SCHEMBL24791508

SCHEMBL24791508

c1ccc(-c2ccc(CNc3cc(N[C@H]4CCCNC4)nc4c(C5CC5)cnn34)cc2)nc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 5/20 0.49
▸ CHEK1 O14757 3/20 0.49
▸ CCNA2 P20248 2/20 0.49
▸ CCNA1 P78396 1/20 0.49
▸ GSK3B P49841 1/20 0.47
▸ CCNT1 O60563 9/20 0.46
▸ CDK7 P50613 5/20 0.43
▸ CDK9 P50750 3/20 0.43
▸ CDK5 Q00535 3/20 0.43
▸ CDK1 P06493 3/20 0.43
▸ CCNE1 P24864 3/20 0.43
▸ CCNH P51946 3/20 0.43
▸ MNAT1 P51948 3/20 0.43
▸ CDK4 P11802 2/20 0.43
▸ CDK6 Q00534 2/20 0.43
▸ CDK8 P49336 1/20 0.43
▸ DYRK3 O43781 1/20 0.42
▸ CLK1 P49759 1/20 0.42
▸ CLK2 P49760 1/20 0.42
▸ CLK3 P49761 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24791510 1.00 CDK2 (0.49) CDK2CHEK1CCNA2CCNA1GSK3B
SCHEMBL24791684 0.95 CDK2 (0.45) CDK2CHEK1CCNA2CCNA1GSK3B
SCHEMBL24791659 0.95 CDK2 (0.45) CDK2CHEK1CCNA2CCNA1GSK3B
SCHEMBL24791683 0.95 CDK2 (0.45) CDK2CHEK1CCNA2CCNA1GSK3B
SCHEMBL24792972 0.93 CDK7 (0.46) CDK2CHEK1CCNA2CCNA1GSK3B
SCHEMBL24791653 0.91 CDK2 (0.47) CDK2CHEK1CCNA2CCNA1GSK3B
SCHEMBL24792980 0.91 CCNT1 (0.52) CDK2CHEK1CCNA2CCNA1GSK3B
SCHEMBL24792971 0.90 CDK2 (0.47) CDK2CHEK1CCNA2CCNA1GSK3B
SCHEMBL24792979 0.88 CSNK2A2 (0.53) CDK2CHEK1CCNA2CCNA1GSK3B
SCHEMBL24791444 0.86 CDK2 (0.49) CDK2CHEK1CCNA2CCNA1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383900-A1 SUBSTITUTED PYRAZOLO [1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE Carrick Therapeutics Limited (IE) 2024-11-21 — — US disclosed
CN-117940427-A Substituted pyrazolo [1,5-a ] pyrimidine-7-amine compounds as CDK inhibitors and therapeutic uses thereof 卡里克治疗有限公司 2024-04-26 — — CN disclosed
WO-2022263604-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE Carrick Therapeutics Limited (IE) 2022-12-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383900-A1 SUBSTITUTED PYRAZOLO [1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE CDK3, CDK1, CDK2 CDK2 3/4885CHEK1 35/4885CCNA2 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback